ECCO12 Highlights Chemotherapies in Major Tumors

Introduction

According to Datamonitor’s estimate, nearly 1.2 million new cases of breast, non-small cell lung and colorectal cancer are expected to be diagnosed in the seven major pharmaceutical markets in 2003. Because of the patient potential, pharmaceutical interest in these cancers is high. This brief examines the key issues in drug therapy for these cancers, covered at ECCO12. 

Scope

The evolving use of docetaxel and paclitaxel for the treatment of breast cancer 

The role of adjuvant chemotherapy and innovative drugs in non-small cell lung cancer (NSCLC) 

The impact of new agents such as Roche’s Xeloda and Sanofi-Synthelabo’s Eloxatin on gold standard therapy for colorectal cancer 

Report Highlights

The superiority of docetaxel over paclitaxel for the treatment of breast cancer has not been conclusively proven in a head-to-head trial despite the issue receiving significant interest at the conference. 

As in AstraZeneca’s Iressa, Genentech/Roche’s Tarceva is being troubled by weak clinical trial data and, as a result, it may take a bumpy ride to approval and struggle to find its footing in the NSCLC market.

Despite the approval of Xeloda and Eloxatin for colorectal cancer, optimal regimens are yet to be determined. Balancing efficacy with safety remains the key issue for colorectal cancer drugs.

Reasons to Purchase

Assess the potential of taxanes to evaluate the market potential for pipeline drugs in breast cancer

Estimate the commercial potential of epidermal growth factor receptor inhibitors for NSCLC to determine the viability of entry into other markets 

Enhance your commercial positioning by understanding the dynamics of current colorectal cancer drugs 

November 2003, 34 pages 

Publisher: Datamonitor Oncology Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a207